Save time and jump to the most important pieces.
Date | Price Target | Rating | Analyst |
---|---|---|---|
11/27/2024 | $3.00 | Buy | Maxim Group |
CRANFORD, N.J., May 14, 2025 /PRNewswire/ -- Citius Oncology, Inc. ("Citius Oncology" or the "Company") (NASDAQ:CTOR), a specialty biopharmaceutical company focused on the development and commercialization of novel targeted oncology therapies, today reported business and financial results for the fiscal second quarter ended March 31, 2025. "In Q2 2025, Citius Oncology advanced its transformation from a development-stage company to a commercial-stage organization. Following FDA approval of LYMPHIR, we intensified our focus on disciplined capital deployment and operational execu
CEO Leonard Mazur to present on Thursday, June 5, 2025, at 3:10 pm ET CRANFORD, N.J., May 5, 2025 /PRNewswire/ -- Citius Pharmaceuticals, Inc. (NASDAQ:CTXR) and its oncology subsidiary, Citius Oncology, Inc. (NASDAQ:CTOR), today announced that Leonard Mazur, Chairman and Chief Executive Officer of both companies, will present at the Jefferies Global Healthcare Conference, taking place June 3 – June 5, 2025 in New York City. Conference Details: Presentation: 3:10 pm ET on Thursday, June 5, 2025* Location: New York City Webcast: A live and archived webcast of the presentation will be available here. A replay will be available for a limited time following the presentation on
CRANFORD, N.J., Feb. 14, 2025 /PRNewswire/ -- Citius Oncology, Inc. ("Citius Oncology" or the "Company") (NASDAQ:CTOR), a specialty biopharmaceutical company focused on the development and commercialization of novel targeted oncology therapies, today reported business and financial results for the fiscal first quarter ended December 31, 2024. Fiscal First Quarter 2025 Business Highlights and Subsequent Developments Engaged Jefferies as exclusive financial advisor to assist in evaluating strategic alternatives aimed at maximizing shareholder value, with multiple active discussi
10-Q - CITIUS ONCOLOGY, INC. (0001851484) (Filer)
8-K - CITIUS ONCOLOGY, INC. (0001851484) (Filer)
8-K - CITIUS ONCOLOGY, INC. (0001851484) (Filer)
4 - CITIUS ONCOLOGY, INC. (0001851484) (Issuer)
4 - CITIUS ONCOLOGY, INC. (0001851484) (Issuer)
4 - CITIUS ONCOLOGY, INC. (0001851484) (Issuer)
Clinical and regulatory success in 2024 expected to drive value in 2025 CRANFORD, N.J., Dec. 27, 2024 /PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius Pharma" or the "Company") (NASDAQ:CTXR), a biopharmaceutical company dedicated to the development and commercialization of first-in-class critical care products today reported business and financial results for the fiscal full year ended September 30, 2024. Fiscal Full Year 2024 Business Highlights and Subsequent Developments Achieved U.S. Food and Drug Administration (FDA) approval of LYMPHIR™ (denileukin diftitox-cxdl), an immunotherapy for the treatment of adults with relapsed or refractory cutaneous T-cell lymphoma (CTCL);Advanced ma
SC 13G/A - CITIUS ONCOLOGY, INC. (0001851484) (Subject)
SC 13G/A - CITIUS ONCOLOGY, INC. (0001851484) (Subject)
SC 13D - CITIUS ONCOLOGY, INC. (0001851484) (Subject)
Maxim Group initiated coverage of Citius Oncology with a rating of Buy and set a new price target of $3.00